ESR1 and breast carcinoma: More recently, a BCL2/FOS gene expression signature was discovered that can delineate breast cancer patients that have poor tamoxifen response [5]; and a Ki67, P53 and GATA3 combination was shown to predict success of hormonal therapy in ER positive patients [6].